301 related articles for article (PubMed ID: 25613440)
1. [Management and costs of chronic pulmonary obstructive disease in France in 2011].
Laurendeau C; Chouaid C; Roche N; Terrioux P; Gourmelen J; Detournay B
Rev Mal Respir; 2015 Sep; 32(7):682-91. PubMed ID: 25613440
[TBL] [Abstract][Full Text] [Related]
2. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France.
Detournay B; Pribil C; Fournier M; Housset B; Huchon G; Huas D; Godard P; Voinet C; Chanal I; Jourdanne C; Durand-Zaleski I;
Value Health; 2004; 7(2):168-74. PubMed ID: 15164806
[TBL] [Abstract][Full Text] [Related]
3. A dynamic population model of disease progression in COPD.
Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; van Genugten ML; Buist AS; Wouters EF; Feenstra TL
Eur Respir J; 2005 Aug; 26(2):223-33. PubMed ID: 16055869
[TBL] [Abstract][Full Text] [Related]
4. [Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months].
Stâmbu I; Stoicescu IP
Pneumologia; 2013; 62(2):86-92. PubMed ID: 23894789
[TBL] [Abstract][Full Text] [Related]
5. Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Société de pneumologie de langue française (summary).
Jouneau S; Dres M; Guerder A; Bele N; Bellocq A; Bernady A; Berne G; Bourdin A; Brinchault G; Burgel PR; Carlier N; Chabot F; Chavaillon JM; Cittee J; Claessens YE; Delclaux B; Deslée G; Ferré A; Gacouin A; Girault C; Ghasarossian C; Gouilly P; Gut-Gobert C; Gonzalez-Bermejo J; Jebrak G; Le Guillou F; Léveiller G; Lorenzo A; Mal H; Molinari N; Morel H; Morel V; Noel F; Pégliasco H; Perotin JM; Piquet J; Pontier S; Rabbat A; Revest M; Reychler G; Stelianides S; Surpas P; Tattevin P; Roche N
Rev Mal Respir; 2017 Apr; 34(4):282-322. PubMed ID: 28552256
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
Chiang CH
Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
[TBL] [Abstract][Full Text] [Related]
7. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
8. Health economic costs of COPD in Sweden by disease severity--has it changed during a ten years period?
Jansson SA; Backman H; Stenling A; Lindberg A; Rönmark E; Lundbäck B
Respir Med; 2013 Dec; 107(12):1931-8. PubMed ID: 23910072
[TBL] [Abstract][Full Text] [Related]
9. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).
Dal Negro RW; Tognella S; Tosatto R; Dionisi M; Turco P; Donner CF
Respir Med; 2008 Jan; 102(1):92-101. PubMed ID: 17881206
[TBL] [Abstract][Full Text] [Related]
10. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
11. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
[TBL] [Abstract][Full Text] [Related]
12. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
13. The costs of exacerbations in chronic obstructive pulmonary disease (COPD).
Andersson F; Borg S; Jansson SA; Jonsson AC; Ericsson A; Prütz C; Rönmark E; Lundbäck B
Respir Med; 2002 Sep; 96(9):700-8. PubMed ID: 12243316
[TBL] [Abstract][Full Text] [Related]
14. Rising total costs and mortality rates associated with admissions due to COPD exacerbations.
Molinari N; Chanez P; Roche N; Ahmed E; Vachier I; Bourdin A
Respir Res; 2016 Nov; 17(1):149. PubMed ID: 27842545
[TBL] [Abstract][Full Text] [Related]
15. [Use of resources and associated costs of chronic obstructive pulmonary disease exacerbations: A population based retrospective study].
Sicras A; Huerta A; Navarro R; Ibañez J
Semergen; 2014; 40(4):189-97. PubMed ID: 24485969
[TBL] [Abstract][Full Text] [Related]
16. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
Punekar YS; Shukla A; Müllerova H
Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].
Jahnz-Rózyk K; Targowski T; From S; Płusa T
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of chronic obstructive pulmonary disease.
Teo WS; Tan WS; Chong WF; Abisheganaden J; Lew YJ; Lim TK; Heng BH
Respirology; 2012 Jan; 17(1):120-6. PubMed ID: 21954985
[TBL] [Abstract][Full Text] [Related]
19. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting.
Miravitlles M; Sicras A; Crespo C; Cuesta M; Brosa M; Galera J; Lahoz R; Lleonart M; Riera MI
Ther Adv Respir Dis; 2013 Jun; 7(3):139-50. PubMed ID: 23653458
[TBL] [Abstract][Full Text] [Related]
20. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; Al MJ; Feenstra TL
Value Health; 2011 Dec; 14(8):1039-47. PubMed ID: 22152172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
